1Mustafa A, EI-Medany A, Hagar HH, et al. Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res, 2006, 53:324-330.
5Koga H, Sakisaka S, Ohishi M, et al. Expression of eyelooxygenase-2 in human hepatoeellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29:688-696.
6Egan LJ, Toruner M. NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach. Ann N Y Acad Sci, 2006, 1072:114-122.
2Butzner JD, Parmar R, Bell CJ, Dalai V. Butyrateenema therapy stimulates mucosal repair in experimental colitis in the rat. Gut, 1996, 38: 568～573.
3Dieleman LA, Palmen MJ, Akol H, Bloemena E,Pena AS, Meuwissen SG, Van Rees EP. Chronicexperimental colitis induced by dextran sulphatesodium (DSS) is characterized by Th1 and Th2 cy-tokines. Clin Exp Immunol, 1998, 114: 385～391.
4Beagley KW, Black CA, Elson CO. Strain differences in susceptibility to TNBS-induced colitis(abstract). Gastroenterology, 1991, 100: A560.
5Ward M. The pathogenesis of Crohn's disease.Lancet, 1977, 2: 903-905.
6Shorter RG, Huizenga KA, Spencer RJ. A working hypothesis for the etiology and pathogenesisof nonspecific inflammatory bowel disease. Am JDig Dis, 1972, 17: 1024～ 1032.
7Kunin S, Gallily R. Recognition and lysis of altered-self cells by macrophages. I. Modification oftarget cells by 2, 4, 6-trinitrobenzene sulphonicacid. Immunology, 1983, 48: 265～272.
8Grisham MB, Volkmer C, Tso P, Yamada T. Metabolism of trinitrobenzene sulfonic acid by the ratcolon produces reactive oxygen species. Gastroenterology, 1991, 101: 540～547.
9Hyams JS, Fizgera JE, Freem WR, et al. Relatiodship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease[J]. Gaslroenlerology, 1993,104:1285 - 1292.
10Breese J, Michie A, Nicholls W, et al. Tumor Necrosis Faclor producing Cells in the Inleslinal Mucosa of Children With Inflammalory Bowel Disease[J]. Gaslroenlerology, 1994,106:1445 -1452.
